- active not recruitingPHASE1, PHASE2
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This study is testing a new drug, HMBD-001, for advanced cancers where a protein called HER3 is active. We want to find the best dose, understand side effects, and see if it helps stop cancer growth, sometimes with another drug called enzalutamide.
United Kingdom - recruitingPHASE3
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
This study looks at a new treatment called Pumitamig for advanced non-small cell lung cancer that hasn't been treated before. It compares Pumitamig to an existing treatment, Pembrolizumab, in people whose cancer cells have a high level of a specific marker called PD-L1.
United States · Argentina · Australia - recruitingPHASE3
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
This study is looking at two different treatments, pumitamig and durvalumab, for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that can't be removed by surgery. It's for patients who have already had chemotherapy and radiation.
United States · Argentina · Australia - recruitingPHASE1
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
This study is testing a new drug, zanzalintinib, alone and with other medicines, for people with advanced cancers like kidney, prostate, and lung cancer. It's looking at safety and if the treatment shrinks tumours.
United States · Australia · Austria - recruitingPHASE3
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
This study looks into a new drug, Datopotamab Deruxtecan (Dato-DXd), for advanced lung cancer. It compares Dato-DXd to a standard treatment, Docetaxel, in patients whose cancer has responded to previous treatments and has a specific marker called TROP2.
United States · Australia · Austria - active not recruitingPHASE2
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
This study looks at new ways to treat advanced non-small cell lung cancer that hasn't spread after initial treatment. It compares two treatments: Durvalumab alone, and Durvalumab combined with Olaparib, to see if the combination helps patients live longer and better.
United States · Belgium · Hungary - active not recruitingPHASE3
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
This study, called POSEIDON, is testing new drug combinations for people with a type of lung cancer called non-small cell lung cancer (NSCLC). It's comparing usual chemotherapy with combinations of two new drugs, durvalumab and tremelimumab, to see if they work better.
United States · Brazil · Bulgaria - active not recruitingPHASE1, PHASE2
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
This study is testing a new cancer medicine, GEN1042, both by itself and with other treatments. It's for people with certain advanced solid tumours where standard treatments haven't worked or aren't available. The main goals are to check its safety and see how well it fights cancer.
United States · Denmark · France - active not recruitingPHASE1, PHASE2
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
This study is looking at new combinations of immunotherapy drugs for people with advanced lung cancer. It combines an existing drug, Cemiplimab, with one of three new drugs (S095018, S095024, or S095029) to see which combination is safe and works best.
United States · Argentina · Australia - recruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
This study is looking at a new combination of treatments for advanced lung cancer. It compares giving two drugs together (sacituzumab tirumotecan and pembrolizumab) against giving pembrolizumab on its own, to see if the combination helps people live longer.
United States · Argentina · Australia - ongoing, recruitingTherapeutic exploratory (Phase II)
ETOP 21-21 BOUNCE: A multicentre, randomised, phase II trial of brigatinib consolidation versus observation or durvalumab in patients with unresectable stage III NSCLC and ALK-rearrangement, after definitive chemo-radiotherapy.
This study is for people with a type of lung cancer called NSCLC with a specific gene change (ALK-rearrangement). It's looking at whether a drug called Brigatinib, given after chemotherapy and radiation, can stop the cancer from growing for longer compared to other treatments or no further treatment.
Spain · Italy · France - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared with Durvalumab in Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer who have not Progressed after Concurrent Platinum-Based Chemoradiation (SKYSCRAPER-03)
This study looks at new treatments for a type of lung cancer that has not spread widely. It compares two drug combinations to see which is better at stopping the cancer from growing after initial treatment.
Poland · Spain · Portugal - active not recruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
This study compares a new medicine, Sacituzumab Tirumotecan, with standard chemotherapy for advanced lung cancer. It’s for people whose cancer has specific genetic changes and has already been treated. We're looking to see if the new medicine helps people live longer and keeps their cancer from growing for longer.
United States · Australia · Brazil - recruitingPHASE2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
This study is looking at a new treatment called HER3-DXd for people with certain advanced solid tumours that haven't responded to other treatments. It aims to see how well it works and if it's safe for different types of cancer, like melanoma, lung cancer, and breast cancer.
United States · Australia · Belgium - recruitingPHASE3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
This study compares two treatments for a specific type of advanced lung cancer. It looks at how well a treatment combining sotorasib with chemotherapy works against one combining pembrolizumab with chemotherapy, focusing on extending life and preventing cancer growth.
United States · Argentina · Australia - active not recruitingPHASE2
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
This study looks at a new treatment called RP1, by itself and with another drug called nivolumab. It's for people with certain advanced cancers like lung cancer, some skin cancers, and specific solid tumours that haven't responded well to previous treatments.
United States · France · Germany - recruitingPHASE1, PHASE2
Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
This study is testing a new medicine, TH9619, for people with advanced cancers like bowel, head and neck, lung, and stomach cancer. It's the first time TH9619 is being given to people, and doctors want to find the safest and most effective dose.
France · Spain · United Kingdom - recruitingPHASE1, PHASE2
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
This study is looking at two new medicines, Elironrasib and Daraxonrasib, for people with advanced cancers that have a specific genetic change called KRAS G12C. Researchers want to see if these medicines are safe and how well they work, both alone and together.
United States · France · Germany - recruiting
Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments
This study asks patients and medical experts in the US, Germany, or Japan about their views on treatments for a type of lung cancer that can be removed with surgery. It helps us understand what is important to them when choosing treatments.
United Kingdom - active not recruitingPHASE1, PHASE2
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
This study looks at a new treatment called M9140 for different advanced cancers like stomach, lung, and pancreatic cancer. It aims to see if it's safe and effective for patients whose cancers have a specific marker called CEACAM5.
United States · Australia · Austria - recruitingPHASE1
A Study of NX-1607 in Adults With Advanced Malignancies
This study is looking into a new treatment called NX-1607 for various advanced cancers, including ovarian, stomach, and lung cancer. It aims to see how safe the treatment is and if it can help fight the cancer, sometimes combined with another drug called Paclitaxel.
United States · United Kingdom - recruitingPHASE1, PHASE2
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
This study is looking at a new drug, GTAEXS617, for people with advanced solid tumours, including certain types of breast, lung, head and neck, and ovarian cancers. We want to see how safe it is, how the body handles it, and if it can shrink tumours.
United States · Belgium · United Kingdom - ongoing, recruitingHuman Pharmacology (Phase I)- Other
Study of Repotrectinib and CYP450 probe Cocktail in Patients with locally advanced or Metastatic Tyrosine Kinase Inhibitors (TKI)-Pretreated ROS1-Positive Non-small Cell Lung Cancer (NSCLC)
This study is looking at a new drug called repotrectinib for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that has a specific problem (ROS1-positive). It aims to understand how the drug works in the body, especially when patients have already tried other treatments.
France · Spain · Italy - recruiting
Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab
This study looks at how a lung cancer medicine called Tislelizumab works in real-life patients in Germany and Austria. It checks how well people do, how safe the medicine is, and their quality of life over up to five years.
Austria · Germany - recruitingPHASE3
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
This study looks at a new drug called taletrectinib for people with a type of lung cancer (NSCLC) that has a specific gene change (ROS1 positive). It aims to see if the drug can stop the cancer from coming back after surgery.
United States · Canada · China - ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
A Phase 1, Open-label, Randomized, 2-Part, 2-Way Crossover Study in Healthy Adult Participants to Assess the Relative Bioavailability of Tablet Formulations of Lazertinib (JNJ-73841937)
This study is looking at how a new drug, Lazertinib, is absorbed by the body. It’s for healthy adults and compares two different tablet versions of the drug to see if they work the same way. This helps make sure future patients get the best possible treatment.
Belgium - active not recruitingPHASE1
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
This early-stage study is testing a new drug, furmonertinib, for advanced lung cancer. It's for people whose cancer has specific genetic changes (EGFR or HER2 mutations) and has progressed after previous treatments. Researchers are looking at its safety and how well it works.
United States · Australia · Canada - recruiting
Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer
This study looks at how well a treatment combining chemotherapy and amivantamab works for advanced lung cancer with specific gene changes. It helps us understand real-life results and safety for people already receiving this treatment through early access programs.
France - active not recruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
This study looks at a new drug, sacituzumab tirumotecan, for people with a type of lung cancer (non-small cell lung cancer) that has specific genetic changes and has worsened after previous treatments. It compares this new drug to a standard chemotherapy combination to see if it improves survival.
United States · Argentina · Canada - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, Randomized, Blinded, Placebo-Controlled Study of Tiragolumab, an Anti- TIGIT Antibody, in Combination with Atezolizumab in Chemotherapy-Naive Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study looks at a new drug, tiragolumab, combined with an existing cancer drug, atezolizumab (Tecentriq), for people with a type of lung cancer called non-small cell lung cancer that hasn't been treated with chemotherapy yet. It aims to see how well this combination works.
Spain · France - ongoing, recruitingTherapeutic exploratory (Phase II)
KEYMAKER-U01 Master Study: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab in Combination with Chemotherapy or with Pembrolizumab Alone in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) KEYMAKER-U01 Substudy 2: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Treatment Naïve Patients with PD-L1 Positive Advanced Non-small Cell Lung Cancer (NSCLC)
This study looks at new drug combinations for advanced non-small cell lung cancer. It combines Pembrolizumab (Keytruda) with other new medicines like rolistobart or MK-4830 to see how well they shrink tumours and help people live longer, while checking for side effects.
Hungary · Italy · Spain - ongoing, recruitingTherapeutic exploratory (Phase II)
A Multicenter, Open-label, Phase 2 study of Intratumoral Vidutolimod (CMP-001) in Combination with Intravenous Cemiplimab in Subjects with Selected Types of Advanced or Metastatic Cancer
This study is testing a new combination of treatments for some advanced cancers. It involves two drugs, Vidutolimod and Cemiplimab, to see how well they shrink tumours. It's a Phase II study, meaning we're looking at how safe and effective this new approach might be.
France - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, Single-Arm Study of Atezolizumab in Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer who have not Progressed after Platinum-Based Concurrent Chemoradiation
This study is testing a new treatment called Tecentriq for a type of lung cancer that has started to grow but hasn't spread widely. It aims to see if Tecentriq can help keep the cancer from growing for a longer time after standard treatments.
Slovenia · Spain - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A phase I of TG6050 in the treatment of patients with metastatic lung cancer
This study is looking into a new treatment called TG6050 for people with lung cancer that has spread. It's the first time this treatment is being given to humans, aiming to see if it's safe and what dose might work best.
France - ongoing, recruitingTherapeutic exploratory (Phase II)
A phase II trial of Atezolizumab plus induction chemotherapy (CT) plus chemo-radiotherapy and Atezolizumab maintenance therapy in non-resectable stage IIIA-IIIB-IIIC non-small cell lung cancer (NSCLC) patients (APOLO)
This study is testing a new way to treat certain advanced non-small cell lung cancer. It combines a drug called Tecentriq with standard chemotherapy and radiotherapy to see if it can stop the cancer from growing for longer.
Spain - authorisedTherapeutic exploratory (Phase II)
Phase II trial of amivantamab plus monochemotherapy in platinum unfit NSCLC patients with EGFR exon20 insertion mutations
This study looks at a new treatment called amivantamab with chemotherapy for people with a specific type of lung cancer (NSCLC) where standard treatments haven't worked well. It aims to see how many people respond to the treatment.
Italy - authorisedTherapeutic exploratory (Phase II)
Hyperprogression upon cemiplimab alone or with chemotherapy in PD-L1 ≥ 50% NSCLC: a biomarker guided phase 2 trial – HYPERBOLIC study
This study looks at a new cancer drug, cemiplimab (Libtayo), sometimes with chemotherapy, for advanced lung cancer. It checks if the cancer grows very quickly in some patients and how safe and effective the treatments are.
Italy - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC whose Tumors Harbor a KRASG12C Mutation in Need of First-Line Treatment (CodeBreak 201)
This study is looking at a new medicine called sotorasib for people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C mutation). The main goal is to see how many patients' tumors shrink or disappear.
Belgium · Spain · Sweden - ongoing, recruitingTherapeutic exploratory (Phase II)
A randomized phase II study of neo-adjuvant chemo/immunotherapy versus chemo-therapy alone for the treatment of locally advanced and potentially resectable non-small cell lung cancer (NSCLC) patients_NADIM II
This study looks at a new way to treat certain lung cancers before surgery. It compares whether adding an immunotherapy drug called OPDIVO to standard chemotherapy works better than chemotherapy alone for advanced non-small cell lung cancer.
Spain - ongoing, recruitingHuman Pharmacology (Phase I)- Other
Phase I Clinical Study to Assess Safety and Efficacy of Repotrectinib Combined with Osimertinib in Patients with Advanced, Metastatic EGFR Mutant NSCLC (TOTEM).
This study is testing a new combination of existing medicines for advanced lung cancer. It aims to see if combining repotrectinib with osimertinib is safe and effective in treating non-small cell lung cancer that has spread and has specific gene changes.
Spain - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination with Atezolizumab Compared with Placebo in Combination with Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
This study is for people with a certain type of advanced lung cancer that hasn't been treated before. It tests a new drug, tiragolumab, combined with an existing drug, atezolizumab, to see if this combination works better than atezolizumab alone. The aim is to find ways to help people live longer and with better quality of life.
Germany · Hungary · Italy